Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Classifica tra le azioni #17992
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Prezzo delle azioni
$1.69
Ultima sincronizzazione: 2026-09-02
Capitalizzazione di mercato
$216.83M
Variazione (1 giorno)
3.38%
Variazione (1 anno)
-66.03%
Paese
US
Scambia Organogenesis Holdings Inc. (ORGO)

Categoria

Il prezzo ORGO con la capitalizzazione del mercato della B
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
ORGO
$1.69
Capitalizzazione di mercato di Organogenesis Holdings Inc.(ORGO)
Capitalizzazione di mercato: $216.83M
A partire dal September 2026, Organogenesis Holdings Inc. ha una capitalizzazione di mercato pari a $216.83M. Questo rende Organogenesis Holdings Inc. la 17992nd azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Organogenesis Holdings Inc. dal 2017 al 2026
ORGO in paragone con la classifica dei più popolari stocks
Il prezzo per ORGO Attivo B Capitalizzazione del mercato a B Risultati
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$42,155.14 $216.83M
$5.424T +2,501,539.97%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$37,116.02 $216.83M
$4.776T +2,202,500.65%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$31,488.85 $216.83M
$4.052T +1,868,563.68%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$28,685.07 $216.83M
$3.691T +1,702,177.25%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$21,327.01 $216.83M
$2.744T +1,265,523.00%